These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 17991541

  • 1. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T, Hara N, Kitamura Y, Komatsubara S.
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [Abstract] [Full Text] [Related]

  • 2. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M.
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [Abstract] [Full Text] [Related]

  • 3. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
    Fang LC, Dattoli M, Taira A, True L, Sorace R, Wallner K.
    Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML.
    Cancer; 2002 Sep 01; 95(5):1028-36. PubMed ID: 12209687
    [Abstract] [Full Text] [Related]

  • 12. [Clinical studies on the prognostic factors in prostate cancer].
    Horii Y, Yoshida T, Hirai S, Yamauchi T.
    Hinyokika Kiyo; 1998 Oct 01; 44(10):701-5. PubMed ID: 9850833
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M, Noda S.
    J Urol; 2001 Sep 01; 166(3):1106-10. PubMed ID: 11490307
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
    Tsurusaki T, Koji T, Sakai H, Kanetake H, Saito Y.
    Clin Cancer Res; 1998 Sep 01; 4(9):2187-94. PubMed ID: 9748138
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.